EFFICACY AND SAFETY OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE IN MIXED ETIOLOGY NONINFECTIOUS CYSTOID MACULAR EDEMA.
Yamamoto Marcus, Hanson Justin, Marin Alejandro I, Gundlach Bradley, Au Adrian, Hou Kirk, Hosseini Hamid, Pettenkofer Moritz, McCannel Colin, Prasad Pradeep
AI Summary
Suprachoroidal triamcinolone effectively reduced noninfectious cystoid macular edema and improved vision across various causes, with a good safety profile, offering a promising treatment option.
Abstract
Purpose
To assess the efficacy and safety of suprachoroidal triamcinolone acetonide in the management of noninfectious cystoid macular edema of various etiologies.
Methods
Retrospective observational study of 61 eyes of 56 patients with noninfectious cystoid macular edema who received suprachoroidal triamcinolone acetonide injection. Primary outcomes were treatment response, central subfield thickness, visual acuity, and intraocular pressure at baseline, 1 month, and 3 months after injection.
Results
Cystoid macular edema etiology included postoperative, uveitis, diabetes mellitus, and retinal vein occlusion. Complete resolution of cystoid macular edema occurred in 34 eyes (58.6%) at 1 month and 23 eyes (50.0%) at 3 months. Median central subfield thickness improved from 430.0 µ m (IQR, 366.0-547.5) to 297.0 µ m (IQR, 277.0-392.0) at 1 month ( P < 0.001) and 326.5 µ m (IQR, 263.9-380.6) at 3 months ( P < 0.001). Visual acuity improved from logarithm of the minimal angle of resolution 0.60 (IQR, 0.40-0.88) [20/80] at baseline to 0.48 (IQR, 0.30-0.70) [20/60] at 1 month ( P = 0.002) and logarithm of the minimal angle of resolution 0.44 (IQR, 0.18-0.88) [20/60] at 3 months ( P = 0.019). Significant intraocular pressure elevation was noted in seven eyes (11.5%) overall, with no occurrences of infection, cataract progression, or suprachoroidal hemorrhage.
Conclusion
Suprachoroidal triamcinolone acetonide demonstrated significant anatomical and functional improvements in eyes with noninfectious cystoid macular edema and a reassuring side effect profile.
MeSH Terms
Shields Classification
Key Concepts5
Complete resolution of cystoid macular edema occurred in 34 eyes (58.6%) at 1 month and 23 eyes (50.0%) at 3 months after suprachoroidal triamcinolone acetonide injection for noninfectious cystoid macular edema of various etiologies.
Median central subfield thickness improved from 430.0 µm (IQR, 366.0-547.5) at baseline to 297.0 µm (IQR, 277.0-392.0) at 1 month (P < 0.001) and 326.5 µm (IQR, 263.9-380.6) at 3 months (P < 0.001) after suprachoroidal triamcinolone acetonide injection in eyes with noninfectious cystoid macular edema.
Visual acuity improved from logarithm of the minimal angle of resolution 0.60 (IQR, 0.40-0.88) [20/80] at baseline to 0.48 (IQR, 0.30-0.70) [20/60] at 1 month (P = 0.002) and logarithm of the minimal angle of resolution 0.44 (IQR, 0.18-0.88) [20/60] at 3 months (P = 0.019) after suprachoroidal triamcinolone acetonide injection in eyes with noninfectious cystoid macular edema.
Significant intraocular pressure elevation was noted in seven eyes (11.5%) overall after suprachoroidal triamcinolone acetonide injection for noninfectious cystoid macular edema, with no occurrences of infection, cataract progression, or suprachoroidal hemorrhage.
A retrospective observational study of 61 eyes of 56 patients was conducted to assess the efficacy and safety of suprachoroidal triamcinolone acetonide in the management of noninfectious cystoid macular edema of various etiologies, including postoperative, uveitis, diabetes mellitus, and retinal vein occlusion.
Related Articles5
Intravitreal Therapy for Uveitic Macular Edema-Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results.
Randomized Controlled TrialSterile Intraocular Inflammation Associated With Faricimab.
Case SeriesTreatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies: A Report by the American Academy of Ophthalmology.
Systematic ReviewMacular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment.
Randomized Controlled TrialExpert Consensus Recommendations for the Management of Ocular Surface Inflammation in Patients With Glaucoma.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.